M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss

The current frontline symptomatic treatment for Alzheimer’s disease (AD) is whole-body upregulation of cholinergic transmission via inhibition of acetylcholinesterase. This approach leads to profound dose-related adverse effects. An alternative strategy is to selectively target muscarinic acetylchol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Bradley, Sophie J., Bourgognon, Julie-Myrtille, Sanger, Helen E., Verity, Nicholas, Mogg, Adrian J., White, David J., Butcher, Adrian J., Moreno, Julie A., Molloy, Colin, Macedo-Hatch, Timothy, Edwards, Jennifer M., Wess, Jurgen, Pawlak, Robert, Read, David J., Sexton, Patrick M., Broad, Lisa M., Steinert, Joern R., Mallucci, Giovanna R., Christopoulos, Arthur, Felder, Christian C., Tobin, Andrew B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5272187/
https://ncbi.nlm.nih.gov/pubmed/27991860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados